Send to

Choose Destination
Expert Opin Drug Discov. 2016 Dec;11(12):1213-1222. Epub 2016 Oct 11.

In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics.

Author information

a Department of Molecular and Systems Biology , Geisel School of Medicine at Dartmouth , Hanover , NH , USA.
b Department of Biomedical Data Science , Geisel School of Medicine at Dartmouth , Lebanon , NH , USA.
c Norris Cotton Cancer Center , Lebanon , NH , USA.


Leukemia is a collection of highly heterogeneous cancers that arise from neoplastic transformation and clonal expansion of immature hematopoietic cells. Post-treatment recurrence is high, especially among elderly patients, thus necessitating more effective treatment modalities. Development of novel anti-leukemic compounds relies heavily on traditional in vitro screens which require extensive resources and time. Therefore, integration of in silico screens prior to experimental validation can improve the efficiency of pre-clinical drug development. Areas covered: This article reviews different methods and frameworks used to computationally screen for anti-leukemic agents. In particular, three approaches are discussed including molecular docking, transcriptomic integration, and network analysis. Expert opinion: Today's data deluge presents novel opportunities to develop computational tools and pipelines to screen for likely therapeutic candidates in the treatment of leukemia. Formal integration of these methodologies can accelerate and improve the efficiency of modern day anti-leukemic drug discovery and ease the economic and healthcare burden associated with it.


Computational drug repositioning; leukemia; molecular docking; network analysis; transcription profiling

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center